The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

BRAF-MEK Inhibitor Combination in BRAF-Mutant Melanoma

Targeted dual pathway inhibition for advanced melanoma harboring BRAF V600 mutations

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is BRAF-MEK Inhibitor Combination in BRAF-Mutant Melanoma?

Combination targeted therapy blocks two sequential kinases in the MAPK signaling pathway preventing BRAF V600-mediated proliferation.

Approved combinations include dabrafenib-trametinib, vemurafenib-cobimetinib and encorafenib-binimetinib for BRAF V600-mutant melanoma.

BRAF V600 mutation testing required for patient selection through validated molecular assays.

Indications include adjuvant therapy after complete resection, advanced unresectable disease and combined approaches with immunotherapy.

Response rates are high with rapid disease control though duration of response is typically limited by acquired resistance.

Symptoms

Common adverse events include pyrexia, fatigue, nausea, diarrhea, rash, arthralgia and headache.
BRAF inhibitor-specific events include cutaneous squamous cell carcinoma (less common with combination), keratoacanthoma and photosensitivity.
MEK inhibitor effects include retinal events (serous retinopathy), left ventricular dysfunction, hypertension and ocular toxicities.
Hepatotoxicity, dermatitis, hand-foot syndrome and uveitis may occur requiring monitoring and management.
Pyrexia syndrome is particularly characteristic of dabrafenib-trametinib combination requiring drug interruption protocols.

Risk Factors

Cardiac comorbidity including reduced left ventricular function increases MEK inhibitor cardiotoxicity risk.
Pre-existing retinal disease requires baseline ophthalmologic evaluation.
Hepatic dysfunction may require dose modification and increased monitoring.
Drug interactions through CYP3A4 metabolism require comprehensive medication review.
Pregnancy and breastfeeding due to teratogenic effects of both agents.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent fever above 38.5°C requires drug interruption and evaluation per pyrexia management protocols.
  • Vision changes including blurred vision or visual loss require urgent ophthalmologic evaluation for retinopathy.
  • Symptoms of cardiac dysfunction including dyspnea or peripheral edema require cardiac evaluation with echocardiography.
  • New skin lesions require dermatologic evaluation given risk of skin cancers.
  • Hepatic dysfunction symptoms (jaundice, abdominal pain) require evaluation and possible drug discontinuation.

Treatment Methods

01
Comprehensive baseline evaluation including cardiac function (LVEF), ophthalmologic examination and dermatologic assessment.
02
Routine monitoring with cardiac function reassessment, ophthalmologic surveillance and dermatologic evaluation throughout treatment.
03
Pyrexia management protocols including drug interruption, antipyretics and dose modification with re-introduction strategies.
04
Adverse event management with dose modification, treatment interruption and supportive care guided by toxicity grade.
05
Multidisciplinary care with oncology, cardiology, ophthalmology and dermatology along with consideration of resistance mechanisms and sequential therapy strategies including immunotherapy options optimizes long-term outcomes.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.